Breast cancer survival rates have improved considerably in the last few decades in Colombia, but factors that increase the likelihood of patients experiencing cardiovascular side effects, like ...

As cancer survival rates improve, cardiovascular complications arising from anticancer therapies have emerged as a critical determinant of long-term patient ...

Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such as trastuzumab. Both types of drugs are major culprits in chemotherapy-induced heart ...

Cardiotoxicity, damage to the heart or cardiovascular system, occurs as an unfortunate side effect associated with many medications, particularly those used for treating cancer. While experts have ...

Please provide your email address to receive an email when new articles are posted on . Obesity may be a predictor of chemotherapy-related cardiotoxicity in patients with breast cancer. Cardiotoxicity ...

Three abstracts presented at this year’s annual meeting of the American Society of Clinical Oncology focused on cardiotoxic effects of cancer treatment and how cardiac disease remains a barrier to ...

Unveiling the influence of SGLT2 inhibitors on clinical outcomes in patients with cancer with therapy-related cardiac dysfunction: A meta-analysis and systemic review. This is an ASCO Meeting Abstract ...

Please provide your email address to receive an email when new articles are posted on . Dexrazoxane reduced the risk for cardiac events and clinical heart failure among women with breast cancer who ...

Eric H. Yang, MD, warns that lifetime cardiovascular risk for patients with breast cancer may exceed the general population as life expectancies grow, emphasizing the need for early intervention. Yang ...

Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such as trastuzumab. Both types of drugs are major culprits in chemotherapy-induced heart ...